Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 2, Amgen announced new interim ...

On June 2, Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial for its drug IMDELLTRA (tarlatamab-dlle). The data were presented at the 2025 ASCO Annual Meeting and ...

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

The Food and Drug Administration granted accelerated approval to the drug, developed by Amgen and branded as Imdelltra, in May. “We were one of the first in the country to start treating patients on ...

7) Amgen's Imdelltra/Imdylltra (tarlatamab), DLL3×CD3-targeting bispecific T-cell engager (BiTE) for extensive stage small cell lung cancer (ES-SCLC), the first DLL3-directed therapy to reach the ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 16 stocks Jim Cramer recently discussed. When a caller asked about ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 16 stocks Jim Cramer recently discussed. A caller asked if it was a ...